Abbvie to record $3.5 billion charge related to schizophrenia drug

(Reuters) – Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shreya Biswas)